Ovarian cancer is a global health concern, affecting over 300 000 women worldwide in 2022. Despite initial success of first-line treatments, about 80% of patients with advanced-stage ovarian cancer experience recurrence, resulting in a five-year survival rate of only 46%. This high relapse rate underlines the need for new therapeutic strategies to improve patient outcomes. A subset of ovarian cancer patients with low ASNS protein levels may respond well to L-asparaginase. However, current formulations, such as Oncaspar®, which is commonly used to treat acute lymphoblastic leukemia in children, are often limited by their toxicity and side effects. To address these challenges, a novel variant has been developed to improve safety, reduce immunogenicity, and enhance tolerability. These advancements could potentially expand its use to other blood cancers and aggressive solid tumors with low ASNS expression. Oncologists could personalize treatments based on tumor characteristics like ASNS levels, identifying patients most likely to benefit. This targeted approach has the potential to deliver better outcomes and enhance quality of life, ultimately improving survival. Beyond patient benefits, new L-asparaginase formulations could also impact the pharmaceutical and biotech industries. By competing with existing treatments like Oncaspar®, these new therapies create opportunities for economic growth through patents and commercialization.